<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200327</url>
  </required_header>
  <id_info>
    <org_study_id>AOIGCSMERRI/2016/RdT01</org_study_id>
    <nct_id>NCT03200327</nct_id>
  </id_info>
  <brief_title>Comparison of Anterior Vaginal Sacrospinofixation With Laparoscopic Promontofixation for the Treatment of Anterior and Apical Genitourinary Prolapse</brief_title>
  <acronym>SAPPRO</acronym>
  <official_title>Comparison of Anterior Vaginal Sacrospinofixation With Laparoscopic Promontofixation for the Treatment of Anterior and Apical Genitourinary Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators anticipate a reduced risk of post-operational de novo stress urinary
      incontinence following surgery for vaginal sacrospinofixation, associated with reduced costs,
      comparable functional and anatomical efficacy and no increase in morbidity and rate of
      dyspareunia with the new treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of de novo problematic stress urinary incontinence, operable or not, between groups response</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>≥ 2 to question 17 of PFDI-20 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>De novo dyspareunia rate the dyspareunia between groups</measure>
    <time_frame>12 months after the initial intervention</time_frame>
    <description>≥ 2 to question 11 of the PISQ-IR questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sexual life between groups</measure>
    <time_frame>12 months after the initial intervention</time_frame>
    <description>PISQ-IR questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention for suburethral band (BSU) in de novo SUI between groups</measure>
    <time_frame>up to 12 months after the initial intervention</time_frame>
    <description>binary: yes/no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare anatomical prolapse symptoms between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>POP-Q questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare functional prolapse symptoms between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>PFDI-20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life associated to pelvic floor issues between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>PFIQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare general quality of life between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>SF12 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare global satisfaction between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>PGI-I questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare perioperational morbidity between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>complication assessed as stage ≥2 on Clavien-Dindo classification, or according to the ICS/IUGA classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare direct and indirect costs of the 2 interventions</measure>
    <time_frame>12 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Prolapse Genital</condition>
  <arm_group>
    <arm_group_label>laparoscopic promontofixation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anterior vaginal sacrospinofixation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>promontofixation</intervention_name>
    <description>reconstruction of cystoceles using a subvesical prosthesis</description>
    <arm_group_label>laparoscopic promontofixation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sacrospinofixation</intervention_name>
    <description>Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route</description>
    <arm_group_label>Anterior vaginal sacrospinofixation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  Patient must be available for 12 month follow-up

          -  Patient is ≥50 and &lt;80 years old

          -  Patient has pelvic prolapse stage 2 or above according to international POP-Q score,
             concerning the anterior and apical compartments, justifying surgical treatment

          -  Patients not having preoperational stress urinary incontinence or having mild stress
             urinary incontinence not causing significant functional problems (response &lt;2 to
             question 17 of PFDI-20 questionnaire). It is possible that patients with hidden stress
             urinary incontinence will be recruited

        Exclusion Criteria:

          -  The subject is participating in an interventional study, or is in a period of
             exclusion determined by a previous study

          -  The patient is under safeguard of justice or state guardianship

          -  The subject refuses to sign the consent

          -  Patient with communication issues preventing comprehension of information and
             administration of questionnaires

          -  Pelvic prolapse not affect anterior and apical compartments, regardless of stage

          -  Patient with preoperative dyspareunia (patients with mild sexual discomfort related to
             prolapse may be included

          -  Patient presents with preoperative stress urinary incontinence responsible of
             significant functional incapacity (response ≥2 to question 17 of PFDI-20
             questionnaire).

          -  Indication for concomitant suburethral sling

          -  Patient with previous history of surgery for stress urinary incontinence

          -  Indication of concomitant perineorrhaphy surgery with or without myorrhaphy (in both
             groups).

          -  Contra-indication for general anesthetic

          -  Current urinary infection

          -  Current vaginal infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de clermont-Ferrand</name>
      <address>
        <city>clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine CAMPAGNE-LOISEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Cosson</last_name>
      <email>michel.cosson@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Cosson</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine Giraudet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HFME - Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gery Lamblin</last_name>
      <email>gery.lamblin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gery Lamblin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Beau-Soleil</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Courtieu</last_name>
      <email>c.courtieu@languedoc-mutualite.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Courtieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Cornille</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Panel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara Compan</last_name>
      <phone>04 67 33 67 33</phone>
      <email>clara.compan@me.com</email>
    </contact>
    <investigator>
      <last_name>Clara Compan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud de Tayrac, MD</last_name>
      <phone>0466686868</phone>
      <email>renaud.detayrac@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud de Tayrac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte Fatton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

